BR0111732A - Prodrogas de 2-deóxi-beta-l-nucleosìdeos - Google Patents

Prodrogas de 2-deóxi-beta-l-nucleosìdeos

Info

Publication number
BR0111732A
BR0111732A BR0111732-7A BR0111732A BR0111732A BR 0111732 A BR0111732 A BR 0111732A BR 0111732 A BR0111732 A BR 0111732A BR 0111732 A BR0111732 A BR 0111732A
Authority
BR
Brazil
Prior art keywords
deoxy
nucleoside
hepatitis
compositions
nucleoside prodrugs
Prior art date
Application number
BR0111732-7A
Other languages
English (en)
Inventor
Martin L Bryant
Gilles Gosselin
Jean-Louis Imbach
Original Assignee
Idenix Cayman Ltd
Univ Montpellier Ii
Ct Nat Da La Rech Scient Cnrs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd, Univ Montpellier Ii, Ct Nat Da La Rech Scient Cnrs filed Critical Idenix Cayman Ltd
Publication of BR0111732A publication Critical patent/BR0111732A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"3'-PRODROGAS DE 2-DEóXI-<225>-L-NUCLEOSìDEOS". A presente invenção se refere a compostos, composições e métodos para o tratamento de um hospedeiro infectado com o vírus da hepatite B. Especificamente, compostos e composições de 3'-ésteres de 2'-deóxi-<225>-L-nucleosídeos são descritos, os quais podem ser administrados tanto sozinhos quanto em combinação com outros agentes anti vírus da hepatite B. Compostos e composições de 3',5'-ésteres de 2'-deóxi-<225>-L-nucleosídeos são descritos, os quais podem ser administrados tanto sozinhos quanto em combinação com outros agentes anti vírus da hepatite B, que são também descritos.
BR0111732-7A 2000-06-15 2001-06-15 Prodrogas de 2-deóxi-beta-l-nucleosìdeos BR0111732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21210000P 2000-06-15 2000-06-15
PCT/US2001/019147 WO2001096353A2 (en) 2000-06-15 2001-06-15 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES

Publications (1)

Publication Number Publication Date
BR0111732A true BR0111732A (pt) 2003-06-24

Family

ID=22789563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111732-7A BR0111732A (pt) 2000-06-15 2001-06-15 Prodrogas de 2-deóxi-beta-l-nucleosìdeos

Country Status (27)

Country Link
EP (1) EP1296995B1 (pt)
JP (1) JP4639032B2 (pt)
KR (2) KR20030032967A (pt)
CN (3) CN1295242C (pt)
AP (1) AP1771A (pt)
AR (1) AR035711A1 (pt)
AT (1) ATE411332T1 (pt)
AU (2) AU6692701A (pt)
BR (1) BR0111732A (pt)
CA (1) CA2413163C (pt)
CZ (1) CZ2003122A3 (pt)
DE (1) DE60136181D1 (pt)
EA (1) EA005774B1 (pt)
ES (1) ES2317912T3 (pt)
IL (3) IL153379A0 (pt)
MA (1) MA27126A1 (pt)
MX (1) MXPA02012443A (pt)
MY (1) MY141594A (pt)
NO (1) NO20026001L (pt)
NZ (2) NZ523632A (pt)
OA (1) OA12384A (pt)
PE (1) PE20020216A1 (pt)
PL (1) PL360404A1 (pt)
UY (1) UY26779A1 (pt)
WO (1) WO2001096353A2 (pt)
YU (1) YU94802A (pt)
ZA (2) ZA200300168B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136620D1 (de) 2000-04-13 2009-01-02 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
EA007867B1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
KR20050055630A (ko) * 2002-06-28 2005-06-13 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
US7186700B2 (en) 2002-09-13 2007-03-06 Idenix Pharmaceuticals, Inc. β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
CN101415719A (zh) 2003-03-20 2009-04-22 微生物化学及药品有限公司 生产2’-脱氧-β-L-核苷的方法
CN1812995A (zh) * 2003-04-28 2006-08-02 艾登尼科斯（开曼）有限公司 工业化规模的核苷合成
EP4032897A1 (en) 2003-05-30 2022-07-27 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
EP2157095A3 (en) 2003-06-30 2010-09-08 Novartis AG Synthesis of beta-L-2-Deoxy nucleosides
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
MX2007016068A (es) 2005-06-17 2008-03-10 Novartis Ag Uso de sanglifehrina en hcv.
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
WO2009152353A2 (en) 2008-06-11 2009-12-17 Lasergen, Inc. Nucleotides and nucleosides and methods for their use in dna sequencing
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN104017020B (zh) 2010-03-31 2017-04-12 吉利德制药有限责任公司 核苷氨基磷酸酯
WO2011123586A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013040257A1 (en) 2011-09-13 2013-03-21 Lasergen, Inc. 5-methoxy. 3'-oh unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing
ME03009B (me) 2011-09-16 2018-10-20 Gilead Pharmasset Llc Metode za lecenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
HUE047777T2 (hu) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
CN112384228A (zh) 2018-04-12 2021-02-19 莫迪斯治疗公司 用于治疗由失衡的核苷酸池引起的疾病的脱氧核苷的前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
SE505648C2 (sv) * 1996-08-30 1997-09-22 Scania Cv Ab Anordning vid ett fordon för monterbar anfästning av en förarplatsmodul
DK2415776T3 (en) * 1998-08-10 2016-07-04 Novartis Ag Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B

Also Published As

Publication number Publication date
CN1452627A (zh) 2003-10-29
CN101012259A (zh) 2007-08-08
CN1295242C (zh) 2007-01-17
EA200300023A1 (ru) 2003-08-28
UY26779A1 (es) 2001-12-28
IL153379A0 (en) 2003-07-06
JP4639032B2 (ja) 2011-02-23
AP2003002713A0 (en) 2003-03-31
ZA200300168B (en) 2004-07-07
PE20020216A1 (es) 2002-04-16
KR20030032967A (ko) 2003-04-26
IL153379A (en) 2007-02-11
YU94802A (sh) 2006-03-03
ES2317912T3 (es) 2009-05-01
EP1296995A2 (en) 2003-04-02
OA12384A (en) 2006-04-17
NZ523632A (en) 2005-03-24
ATE411332T1 (de) 2008-10-15
JP2004533403A (ja) 2004-11-04
AR035711A1 (es) 2004-07-07
KR20070048277A (ko) 2007-05-08
ZA200404306B (en) 2005-06-15
PL360404A1 (en) 2004-09-06
CA2413163A1 (en) 2001-12-20
NO20026001D0 (no) 2002-12-13
CA2413163C (en) 2008-11-18
NZ535246A (en) 2006-06-30
AU6692701A (en) 2001-12-24
EP1296995B1 (en) 2008-10-15
DE60136181D1 (de) 2008-11-27
MA27126A1 (fr) 2005-01-03
NO20026001L (no) 2003-02-12
IL178864A0 (en) 2007-03-08
WO2001096353A3 (en) 2002-04-18
CN1900104A (zh) 2007-01-24
EA005774B1 (ru) 2005-06-30
WO2001096353A2 (en) 2001-12-20
CZ2003122A3 (cs) 2003-06-18
MXPA02012443A (es) 2004-09-10
AP1771A (en) 2007-08-23
AU2001266927B2 (en) 2006-12-14
MY141594A (en) 2010-05-14

Similar Documents

Publication Publication Date Title
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2&#39;-ДЕЗОКСИНУКЛЕОЗИДОВ
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
BRPI0511834A (pt) métodos por tratar hepatite c
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31&#39; dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
BRPI0414045A (pt) administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
BR0206266A (pt) Heterocìclicos de difenila substituìda útil para tratar infecção por hcv
BR9712544A (pt) Inibidores de proteases de serina, particularmente protease ns3 do vìrus hapatite c
BRPI0515596A (pt) composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
PT1404347E (pt) Nucleosidos 4&#39;-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
BRPI0514176A (pt) inibidores de replicação de hcv
BR0311132A (pt) Inibidores do vìrus da hepatite c
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
BR0313755A (pt) Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
ATE555794T1 (de) Heilmittel gegen hepatitis
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
WO2009008924A3 (en) Methods of preventing and treating viral infections by inhibiting the deisgylation activity of otu domain-containing viral proteins

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.